Mounjaro, Zepbound Lowers Risk of Cardiovascular Death by 62%

• GLP-1 weight reduction medicines containing tirzepatide (Mounjaro, Zepbound) can cut back heart-related well being dangers for individuals with severe coronary heart situations, based on new analysis.
• Consultants say the center well being advantages are produced by the medicine’ capability to assist individuals drop a few pounds and management blood sugar ranges.
• Individuals utilizing these medicines must also keep a wholesome life-style, together with every day train and a balanced weight-reduction plan, to keep up total well being.

Weight reduction medicines containing the lively ingredient tirzepatide considerably cut back cardiovascular dangers in individuals with severe coronary heart situations, based on new analysis.

Tirzepatide medicines are often prescribed to assist deal with type 2 diabetes.

In line with a news release for the 2 research, tirzepatide’s capability to manage blood sugar levels and promote weight reduction delivers “significant cardiovascular advantages.” Whereas prior analysis has established these advantages, their impacts on sufferers present process interventional coronary heart procedures haven’t but been extensively evaluated.

Notably, the researchers discovered a 62% decrease danger of dying amongst members receiving tirzepatide who underwent a PCI process.

“GLP-1 agonists symbolize an vital evolution in cardiometabolic care,” stated SCAI President Srihari Naidu, MD, an interventional heart specialist, within the information launch.

“Clinicians already acknowledge the advantages of glycemic management and weight discount, however we are actually starting to grasp how these therapies can enhance outcomes in sufferers present process transcatheter cardiovascular interventions.”

Consultants not concerned within the new research say the analysis helps earlier research on the cardiovascular advantages of weight reduction medicine.

“These findings are in keeping with what we’re seeing broadly that medicines like tirzepatide are usually not simply weight reduction medicine however have significant cardiometabolic advantages,” stated Kevin Shah, MD, a heart specialist and this system director of Coronary heart Failure Outreach at MemorialCare Coronary heart & Vascular Institute on the Lengthy Seashore Medical Heart. “We do want potential research to validate the findings from these analyses.”

They recognized grownup members with sort 2 diabetes who obtained GLP-1 medicine containing tirzepatide or older medicines with the lively ingredient dulaglutide on the time of their PCI process.

The researchers didn’t evaluate tirzepatide medicine with medicines that comprise the lively ingredient semaglutide, equivalent to Ozempic and Wegovy.

In all, the researchers examined the medical data of 1,281 examine members. One month after PCI, they reported that the members who used tirzepatide medicine skilled decrease charges of main antagonistic cardiovascular occasions, equivalent to:

They famous there was no distinction in charges of stroke amongst members utilizing tirzepatide medicine and people utilizing dulaglutide medicines.

One yr after PCI, researchers noticed reductions in MACE, myocardial infarction, and coronary heart failure exacerbation, remaining constant after one yr. There have been additionally additional reductions in mortality, stroke, and cardiac arrest at one yr.

“The examine provides on extra knowledge to what we’ve already beforehand identified about GLP-1 containing brokers: these medicine hope to cut back danger for cardiovascular issues from weight problems,” stated Yu-Ming Ni, MD, a heart specialist and lipidologist at MemorialCare Coronary heart and Vascular Institute at Orange Coast Medical Heart in Fountain Valley, CA. Ni wasn’t concerned within the examine.

“This affected person inhabitants on this examine is routinely increased danger as a result of they want an intervention for his or her situations,” Ni instructed Healthline. “Consequently, seeing a discount in danger of cardiovascular occasions is promising, albeit not shocking.”

In a second study, researchers from the College of Texas Medical Department, Houston, TX, used the TriNetX database to determine adults with weight problems who underwent TAVR from January 2020 to January 2025.

They grouped the members based mostly on whether or not or not they had been prescribed tirzepatide medicines.

In line with a news release, members who didn’t obtain tirzepatide “skilled worse outcomes over time, with decrease event-free survival.”

They stated the members who didn’t take tirzepatide additionally confronted a 54% increased danger of hospitalization for acute coronary heart failure.

They added that sufferers who didn’t take tirzepatide skilled main antagonistic cardiovascular occasions 44% extra often.

Researchers, nonetheless, famous that they noticed no important variations between teams in charges of ischemic stroke, acute myocardial infarction, and acute kidney harm.

Cheng-Han Chen, MD, an interventional heart specialist and the medical director of the Structural Coronary heart Program at MemorialCare Saddleback Medical Heart in Laguna Hills, CA, stated this new analysis gives helpful data for medical professionals. Chen wasn’t concerned within the research.

“These outcomes add to our quickly rising proof of the useful results of GLP-1 agonists throughout a broad vary of cardiometabolic situations,” he instructed Healthline.

Nevertheless, Jackie DesJardin, MD, a heart specialist and an assistant medical professor of drugs on the College of California San Francisco’s Division of Cardiology, cautioned that there could also be extra to those outcomes than merely the medicines. DesJardin wasn’t concerned within the research.

“The dramatic reductions seen right here, greater than 50% decrease coronary heart assault danger inside only one month, are just too giant to be defined by the drug alone,” she instructed Healthline.

“Tirzepatide is new and costly, and the sufferers who obtain it are typically extra prosperous and higher related to care. Regardless of the creator’s greatest makes an attempt to regulate for these elements, these socioeconomic variations might simply be driving a number of the variations in outcomes.”

Latest analysis has proven that weight reduction medicines that comprise tirzepatide or semaglutide have numerous health benefits.

An August 2025 study reported that each forms of GLP-1 medicine can cut back the chance of hospitalization and dying in individuals with a typical sort of coronary heart failure.

A February 2026 study said that the capsule model of the semaglutide drug Wegovy might help decrease the center failure danger for individuals with sort 2 diabetes.

Consultants say the center well being advantages from GLP-1 medicine are derived from the medicines’ capability to assist individuals drop a few pounds and handle blood sugar ranges, amongst different elements.

“GLP1 brokers equivalent to semaglutide and tirzepatide promote weight reduction, cut back insulin resistance, and cut back liver fats,” stated Ni. “All of those organic enhancements have been proven to [reduce] the chance for coronary heart illness.”

“Improperly managed diabetes can harm the center in some ways,” stated Chen. “Extra blood sugar will increase irritation within the blood vessel partitions, resulting in plaque buildup, which might trigger coronary heart assaults and coronary heart muscle injury. The surplus blood sugar may also result in dysfunction of the center muscle straight and trigger it to change into stiffer and pump blood much less effectively.”

“Tirzepatide works by mimicking two pure intestine hormones which can be launched after consuming, resulting in extra weight reduction and higher management of the foremost drivers of cardiovascular disease: blood sugar, blood stress, and ldl cholesterol,” added DesJardin.

“There may be additionally rising proof that these medicines could have direct results on the center and blood vessels, lowering irritation, serving to blood vessels calm down, defending coronary heart muscle cells, and slowing plaque buildup in arteries.”

Consultants say it’s vital for individuals taking tirzepatide and semaglutide medicine to understand that these medicines merely suppress an individual’s urge for food.

“[GLP-1 drugs] are efficient, however these medicines work greatest as a part of a broader plan of life-style adjustments,” Shah instructed Healthline. “Sufferers needs to be monitored carefully for unwanted side effects and decide long-term objectives on this remedy class.”

Ni stated that weight reduction medicines are supposed to be a short-term answer whereas life-style habits produce long-term outcomes.

“I counsel sufferers to make use of these medicines at the side of a broader life-style change aim,” he stated.

“Even when my sufferers are utilizing this for diabetes or cardiovascular prevention, it nonetheless is significant to switch weight-reduction plan, bodily exercise, train, sleep patterns, and different life-style measures to enhance total well being. I discover my sufferers which can be profitable at altering the best way they dwell to be more healthy can get off these medicines simpler down the street and never regain the burden.”